Literature DB >> 16395110

Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.

Sabine C de Greeff1, Hester E de Melker, Lodewijk Spanjaard, Leo M Schouls, Arie van Derende.   

Abstract

Routine vaccination with a single dose of conjugated meningococcal C vaccine at 14 months and a catch-up campaign have reduced the incidence of meningococcal C disease in the Netherlands. In contrast to countries where routine vaccination is given in infancy, vaccine failures were not reported. This suggests that one dose of conjugated vaccine in the second year of life might offer longer lasting protection against meningococcal C disease than 3 doses in infancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395110     DOI: 10.1097/01.inf.0000195594.41449.c6

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  29 in total

1.  Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients.

Authors:  A Meerveld-Eggink; O de Weerdt; R M de Voer; G A M Berbers; H van Velzen-Blad; B J Vlaminckx; D H Biesma; G T Rijkers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-24       Impact factor: 3.267

2.  Developmental strategy for a new Group A meningococcal conjugate vaccine (MenAfriVacR).

Authors:  Prasad S Kulkarni; Suresh S Jadhav; F Marc LaForce
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

3.  Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.

Authors:  Maria Grazia Pascucci; Valentina Di Gregori; Gabriella Frasca; Paola Rucci; Alba Carola Finarelli; Laura Moschella; Bianca Maria Borrini; Francesca Cavrini; Giovanna Liguori; Vittorio Sambri; Paolo Bonanni; Maria Pia Fantini
Journal:  Hum Vaccin Immunother       Date:  2013-12-30       Impact factor: 3.452

Review 4.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

5.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

6.  Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?

Authors:  Richarda M de Voer; Fiona R M van der Klis; Laetitia E M Niers; Ger T Rijkers; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

Review 7.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

8.  Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005.

Authors:  S C de Greeff; H E de Melker; L M Schouls; L Spanjaard; M van Deuren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-21       Impact factor: 3.267

9.  Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.

Authors:  Hiltsje Hepkema; Koen B Pouwels; Arie van der Ende; Tjalke A Westra; Maarten J Postma
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 10.  Global practices of meningococcal vaccine use and impact on invasive disease.

Authors:  Asad Ali; Rabab Zehra Jafri; Nancy Messonnier; Carol Tevi-Benissan; David Durrheim; Juhani Eskola; Florence Fermon; Keith P Klugman; Mary Ramsay; Samba Sow; Shao Zhujun; Zulfiqar Bhutta; Jon Abramson
Journal:  Pathog Glob Health       Date:  2014-01       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.